Research graph
References from LncTx: A network-based method to repurpose drugs acting on the survival-related lncRNAs in lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.mayocp.2019.01.013
10.1016/j.mayocp.2019.01.013 · External reference
Precision diagnosis and treatment for advanced non-small-cell lung cancer
10.1056/nejmra1703413 · 2017 · External reference
10.1001/jama.2019.11058
10.1001/jama.2019.11058 · External reference
Changes in lung cancer treatment as a result of the coronavirus Disease 2019 Pandemic
10.1001/jamaoncol.2020.4408 · 2020 · External reference
10.1016/s0140-6736(16)30958-8
10.1016/s0140-6736(16)30958-8 · External reference
10.1056/nejmoa1916623
10.1056/nejmoa1916623 · External reference
10.1056/nejmoa044238
10.1056/nejmoa044238 · External reference
10.1056/nejmoa040938
10.1056/nejmoa040938 · External reference
10.1056/nejmoa0810699
10.1056/nejmoa0810699 · External reference
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa1704795 · 2017 · External reference
10.1056/nejmoa1917346
10.1056/nejmoa1917346 · External reference
10.1038/d41586-021-00314-6
10.1038/d41586-021-00314-6 · External reference
10.1146/annurev-biochem-051410-092902
10.1146/annurev-biochem-051410-092902 · External reference
10.1038/s41580-020-00315-9
10.1038/s41580-020-00315-9 · External reference
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
10.1038/s41375-018-0067-3 · 2018 · External reference
10.1038/nrd.2018.93
10.1038/nrd.2018.93 · External reference
10.1073/pnas.1600008113
10.1073/pnas.1600008113 · External reference
10.1038/nrd.2016.117
10.1038/nrd.2016.117 · External reference
MALAT1: A druggable long non-coding RNA for targeted anti-cancer approaches
10.1186/s13045-018-0606-4 · 2018 · External reference
10.1038/sj.onc.1206928
10.1038/sj.onc.1206928 · External reference
10.1097/jto.0b013e3182307eac
10.1097/jto.0b013e3182307eac · External reference
Functions of lncRNA HOTAIR in lung cancer
10.1186/s13045-014-0090-4 · 2014 · External reference
Roles of HOTAIR in lung cancer susceptibility and prognosis
10.1002/mgg3.1299 · 2020 · External reference
10.1016/j.cell.2007.06.014
10.1016/j.cell.2007.06.014 · External reference
10.1186/s12920-021-01137-0
10.1186/s12920-021-01137-0 · External reference
10.1038/nature11003
10.1038/nature11003 · External reference
10.1016/j.cell.2016.06.017
10.1016/j.cell.2016.06.017 · External reference
10.1158/2159-8290.cd-15-0235
10.1158/2159-8290.cd-15-0235 · External reference
Machine learning and feature selection for drug response prediction in precision oncology applications
10.1007/s12551-018-0446-z · 2019 · External reference
10.1158/1078-0432.ccr-18-4117
10.1158/1078-0432.ccr-18-4117 · External reference
Machine learning approaches to drug response prediction: challenges and recent progress
2020 · External reference
10.1093/bib/bbz171
10.1093/bib/bbz171 · External reference
Predicting drug response of tumors from integrated genomic profiles by deep neural networks
2019 · External reference
10.1016/j.ccell.2020.09.014
10.1016/j.ccell.2020.09.014 · External reference
10.1073/pnas.1909998116
10.1073/pnas.1909998116 · External reference
10.1038/nrg2918
10.1038/nrg2918 · External reference
10.1038/nrg1272
10.1038/nrg1272 · External reference
10.1038/s42254-020-00264-4
10.1038/s42254-020-00264-4 · External reference
10.1016/j.physrep.2019.12.004
10.1016/j.physrep.2019.12.004 · External reference
10.1038/s41467-019-09186-x
10.1038/s41467-019-09186-x · External reference
10.1038/ncomms10331
10.1038/ncomms10331 · External reference
10.1039/c9sc04336e
10.1039/c9sc04336e · External reference
Network-based technologies for early drug discovery
10.1016/j.drudis.2017.12.001 · 2018 · External reference
10.1016/j.tips.2016.10.011
10.1016/j.tips.2016.10.011 · External reference
10.1038/nchembio.118
10.1038/nchembio.118 · External reference
Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II Colorectal Cancer
10.1001/jamaoncol.2015.3413 · 2016 · External reference
Identification of high-quality cancer prognostic markers and metastasis network modules
2010 · External reference
TRANSFAC ® : Transcriptional regulation, from patterns to profiles
10.1093/nar/gkg108 · 2003 · External reference
The IntAct molecular interaction database in 2010
10.1093/nar/gkp878 · 2009 · External reference
MINT, the molecular interaction database: 2009 update
10.1093/nar/gkp983 · 2009 · External reference
The BioGRID Interaction Database: 2011 update
10.1093/nar/gkq1116 · 2010 · External reference
Human Protein Reference Database—2009 update
10.1093/nar/gkn892 · 2008 · External reference
10.1093/nar/gkj102
10.1093/nar/gkj102 · External reference
10.1073/pnas.0610772104
10.1073/pnas.0610772104 · External reference
10.1093/nar/gkm936
10.1093/nar/gkm936 · External reference
10.1093/nar/gks1111
10.1093/nar/gks1111 · External reference
10.1093/nar/gkj067
10.1093/nar/gkj067 · External reference
Identification of lncRNA functions in lung cancer based on associated protein-protein interaction modules
2016 · External reference
10.1007/978-3-319-24277-4
10.1007/978-3-319-24277-4 · External reference
10.1038/nature13385
10.1038/nature13385 · External reference
Analysis of Survival Data under the Proportional Hazards Model
1975 · External reference
Guilt by association: contextual information in genome analysis
10.1101/gr.10.8.1074 · 2000 · External reference
10.1038/nmeth.2728
10.1038/nmeth.2728 · External reference
DAVID: Database for annotation, visualization, and integrated discovery
10.1186/gb-2003-4-9-r60 · 2003 · External reference
10.1093/nar/gkv007
10.1093/nar/gkv007 · External reference
10.1093/bioinformatics/btp616
10.1093/bioinformatics/btp616 · External reference
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
10.1093/nar/gkv1507 · 2015 · External reference
10.25080/tcwv9851
10.25080/tcwv9851 · External reference
pROC: an open-source package for R and S+ to analyze and compare ROC curves
10.1186/1471-2105-12-77 · 2011 · External reference
10.32614/rj-2014-008
10.32614/rj-2014-008 · External reference
Computing and Displaying Isosurfaces in R
10.18637/jss.v028.i01 · 2008 · External reference
Topotecan for relapsed small-cell lung cancer: Systematic Review and Meta-Analysis of 1347 Patients
10.1038/srep15437 · 2015 · External reference
Update on the role of topotecan in the treatment of non-small cell lung cancer
10.1634/theoncologist.9-90006-43 · 2004 · External reference
Role of topotecan in non-small cell lung cancer: a review of literature
10.14740/wjon950e · 2015 · External reference
10.1016/j.cllc.2013.08.001
10.1016/j.cllc.2013.08.001 · External reference
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
10.1016/s2352-3026(18)30030-9 · 2018 · External reference
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
2020 · External reference
LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma
10.1136/gutjnl-2013-305806 · 2014 · External reference
SPSNet: subpopulation-sensitive network-based analysis of heterogeneous gene expression data
10.1186/s12918-018-0538-1 · 2018 · External reference
Long non-coding RNAs regulate drug resistance in cancer
2020 · External reference
10.1097/jcma.0000000000000313
10.1097/jcma.0000000000000313 · External reference
A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC)
10.1097/jto.0b013e318145b2e5 · 2007 · External reference
Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells
10.1002/jcp.29924 · 2021 · External reference
10.1038/cddis.2013.442
10.1038/cddis.2013.442 · External reference
10.1093/neuonc/noq193
10.1093/neuonc/noq193 · External reference
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
10.1038/s41416-018-0322-4 · 2018 · External reference
10.1158/1078-0432.ccr-19-2808
10.1158/1078-0432.ccr-19-2808 · External reference
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B
10.1200/jco.1994.12.6.1113 · 1994 · External reference
A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors
10.1158/1078-0432.ccr-11-1101 · 2011 · External reference
Preclinical toxicity of AZD7969: Effects of GSK3β inhibition in adult stem cells
10.1177/0192623314544468 · 2015 · External reference
